[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"immunocompromised\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:immunocompromised":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,49,78,103,136,163],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100347835","phase-3-phase-iii-das181-lower-tract-piv-infection-in-immunocompromised-subjects-substudy-das181-for-covid-19-rct-study-100347835",false,"NCT03808922","Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study","A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects","Inclusion Criteria:\n\n1. At the time of randomization, requires supplemental oxygen ≥2 LPM due to hypoxemia.\n2. Immunocompromised, as defined by one or more of the following:\n\n   * Received an autologous or allogeneic hematopoietic stem cell transplantation (HSCT) at any time in the past\n   * Received a solid organ transplant at any time in the past\n   * Has been or is currently being treated with chemotherapy for hematologic malignancies (e.g., leukemia, myeloma, lymphoma) and\u002For solid tumor malignancies (e.g., lung, breast, brain cancer) at any time in the past\n   * Has an immunodeficiency due to congenital abnormality (only applicable to subjects age \\\u003C 18 years old) or pre-term birth (only applicable to subjects age ≤ 2 years old)\n3. Has, within 3 days prior to randomization, a confirmed LRTI with a sialic acid dependent respiratory virus\n4. If female, subject must meet one of the following conditions:\n\n   * Not be of childbearing potential or\n   * Be of childbearing potential and have a negative urine\u002Fserum pregnancy test and agrees to practice an acceptable method of contraception\n5. Non-vasectomized males are required to practice effective birth control methods\n6. Capable of understanding and complying with procedures as outlined in the protocol\n7. Provides signed informed consent prior to the initiation of any screening or study-specific procedures\n\nFor COVID-19 sub study:\n\n1. Be ≥18 years of age\n2. Provide adequate medical history to permit accurate stratification (but health status may be healthy, high-risk conditions, or immunocompromised).\n3. Prior to SARS CoV 2 infection, has the ability to carry out self-care activities of daily living (basic ADL)\n4. Have lower respiratory tract infection (LRTI) confirmed by CT imaging, with or without contrast, to involve at least 2 lobes of the lung.\n5. Has laboratory-confirmation of the presence of SARS CoV 2 in the respiratory tract by at least one of the following samples\n6. Satisfy inclusion criteria #1, 4, 5, 6, 7 of the main study\n\nExclusion Criteria:\n\n1. Subjects may not be on hospice care or, in the opinion of the investigator, have a low chance of survival during the first 10 days of treatment\n2. Subjects with Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), or Alkaline Phosphatase (ALP) ≥3x ULN and Total Bilirubin (TBILI) ≥2x ULN Note: Subjects with ALT\u002FAST\u002FALP ≥ 3x ULN AND TB ≥2x ULN that have been chronically stable (for \\>1 year on more than one assessments) due to known liver pathology including malignancy (primary or metastasis), chronic medications, transplantation, or chronic infection will not be excluded\n3. Female subjects breastfeeding or planning to breastfeed at any time through 30 days after the last dose of study drug\n4. Subjects taking any other investigational drug used to treat pulmonary infection.\n5. Psychiatric or cognitive illness or recreational drug\u002Falcohol use that, in the opinion of the principal investigator, would affect subject safety and\u002For compliance\n6. Subjects with known hypersensitivity to DAS181 and\u002For any of its components\n7. Subjects with severe sepsis due to either their baseline SAD-RV infection or a concurrent viral, bacterial, or fungal infection and meet at least one of the following criteria:\n\n   * Has evidence of vital organ failure outside of the lung (e.g., liver, kidney)\n   * Requires vasopressors to maintain blood pressure\n\nFor COVID-19 sub study:\n\n1. Subjects requiring invasive mechanical, Bi-PAP or CPAP ventilation at randomization.\n2. Subjects receiving any other investigational or empiric treatment for SARS-2-CoV (either as part of a clinical trial or under emergency approval (approved agents for the management of symptoms, e.g., fever, are permitted).\n3. Subjects who are known HIV-positive (and not undetectable at most recent HIV RNA assessment)\n4. Subjects who are currently taking immunomodulating biologics (e.g, interferons, interleukin)\n5. Subjects with severe sepsis due to either their SARS-CoV-2 infection or a concurrent viral, bacterial, or fungal infection and meeting at least one of the following criteria:\n\n   * Have evidence of vital organ failure outside of the lung (e.g., liver, kidney)\n   * Require vasopressors to maintain blood pressure\n6. Subjects meeting exclusion criteria #2, 3, 5 and 6 of the main study","ALL",{"count":18,"type":19},274,"ESTIMATED","INTERVENTIONAL",[22],"PHASE3","This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection.\n\nIt also contains a sub-study to enroll patients with severe COVID-19.",[25,26,27,28],"Lower Respiratory Tract Infection","Parainfluenza","Immunocompromised","COVID-19",[26,30,27,25,31,32,33,34,35],"PIV","LRTI","COVID19","SARS-CoV-2","Coronavirus","Ansun","RECRUITING","2026-06-18",{"date":39,"type":40},"2026-06-23","ACTUAL",{"date":42,"type":40},"2019-05-23",{"date":44,"type":19},"2028-09-01",{"name":46,"class":47},"Ansun Biopharma, Inc.","INDUSTRY",28,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":20,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100563397","alpha-radiation-emitters-device-dart-for-the-treatment-of-cutaneous-scc-for-immunocompromised-patients-100563397","NCT06615635","Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients","A Pivotal, Single Arm, Open Label Clinical Study to Assess the Safety and Efficacy of Intratumoral Alpha DaRT224 for the Treatment of Immunocompromised Patients With Cutaneous Squamous Cell Carcinoma","DaRT","Inclusion Criteria:\n\n* 1\\. Patients with cutaneous SCC histologically confirmed 2. Histopathological confirmation within 6 months of enrollment provided no tumor treatment occurred between the biopsy and enrollment 3. Immunocompromised due to any primary or secondary immunodeficiencies Measurable disease according to RECIST v 1.1.\n\n  4\\. Patient able and willing to undergo multiple CT scans 5. Tumor size ≤7 cm, at the longest diameter. 6. Single lesion per subject. 7. Targeted lesion must be technically amenable for complete coverage (including margins) by the DaRT seeds. Targets will be deemed technically amenable for complete coverage if there are entry and exit vectors for placement that are not hindered by bone or major vessels or other vital organs (eg. eye) as decided by treating physician and sponsor.\n\n  8\\. Interstitial implant indication validated by multidisciplinary team. 9. ECOG Performance Status ≤2. 10. Life expectancy ≥12 months. 11. Subjects male\u002F female ≥18. 12. Willing and have the ability to provide signed Informed Consent. 13. Patients, male and female, with reproductive potential (including women who are menopausal for less than a year and not surgically sterilized), must practice acceptable effective methods of birth control, such as barrier methods, condom or diaphragm with spermicide or abstinence. Birth control should be continued for 1 year after the DaRT insertion visit.\n\n  14\\. Women with childbearing potential must provide a negative pregnancy test during the screening period and up to V1, prior to the DaRT insertion procedure.\n\n  15\\. Blood tests values:\n  * Platelets ≥100,000 mm3,\n  * Total bilirubin ≤ 1.5xULN,\n  * AST ≤2.5xULN,\n  * SGOT ≤2.5xULN,\n  * SGPT ≤2.5xULN,\n  * Alkaline Phosphatase ≤2.5xULN.\n  * Creatinine Clearance ≥30 ml\u002Fmin.\n  * INR or Prothrombin time ≤1.5xULN.\n\nExclusion Criteria:\n\n* 1\\. Distant or nodal metastatic disease (according to the TNM staging system - N+ or M1 patients are excluded).\n\n  2\\. T4 disease 3. extensive PNI 4. Previously untreated cutaneous SCC 5. Mucosal SCC. 6. Inability to fully cover the entire volume with DaRT seeds 7. Inability to place DaRT seeds into tumor due to inaccessibility by presence of bones or major vessels or vital organs 8. Inability or unwillingness to undergo multiple CT scans 9. Patients receiving any of the following within 4 weeks of enrollment:\n  1. Antineoplastic systemic chemotherapy or biological therapy\n  2. Immunotherapy\n  3. Investigational agents other than the study intervention\n  4. Radiation therapy\n  5. Live vaccines within 30 days prior to the first dose of trial treatment and while participating in the trial.\n\n     10\\. Longest tumor diameter \\>7 cm. 11. Tumor with keratoacanthoma histology. 12. Known hypersensitivity to any component of treatment. 13. Clinically significant cardiovascular disease e.g., cardiac failure of New York Heart Association class III-IV, uncontrolled coronary artery disease, cardiomyopathy, uncontrolled arrhythmia, uncontrolled hypertension, history of myocardial infarction in the last 12 months.\n\n     14\\. Any medical or Psychiatric illness, which in the opinion of the investigator would compromise the patient's ability to tolerate treatment and to adhere to the clinical trial protocol.\n\n     15\\. Serious medical comorbidities that, in the opinion of the investigator, may affect subject compliance and\u002For interpretation of treatment safety or effectiveness.\n\n     16\\. High probability of protocol non-compliance (in opinion of investigator). 17. Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT.\n\n     18\\. Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.\n\n     19\\. Patients do not agree to use adequate contraception (vasectomy or barrier method of birth control) prior to study entry and for 1 year after the DaRT insertion visit.\n\n     20\\. Breastfeeding or pregnant women 21. Tattoos scars, body jewelry (e.g., nose rings) or other identifying marks which cannot be adequately hidden on digital photos or other identifying marks which cannot be adequately hidden on digital photos","18 Years",{"count":48,"type":19},[60],"NA","This is a multi-center clinical study enrolling up to 28 participants. The primary objectives are to determine the objective response rate (ORR) established by the confirmed best overall response (BOR) following intratumoral administration of DaRT - Diffusing Alpha-Emitters Radiation Therapy. Secondary objectives are to:\n\n1. Determine Progression Free Survival (PFS) up to 12 months after Alpha DaRT sources insertion.\n2. Assess Overall Survival (OS) of patients treated with DaRT up to 12 months.\n3. Assess Local control up to 12 months after DaRT insertion.",[63,64,27,65,66,67],"Squamous Cell Carcinoma","Alpha Radiation","Carcinoma, Squamous","Skin Cancer","Brachytherapy","2026-06-15",{"date":70,"type":40},"2026-06-16",{"date":72,"type":40},"2026-01-01",{"date":74,"type":19},"2026-12",{"name":76,"class":47},"Alpha Tau Medical LTD.",11,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":20,"phases":87,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":102},"100318421","phase-1-donor-t-cell-therapy-in-treating-immunocompromised-patients-with-adenovirus-related-disease-100318421","NCT03425526","Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease","Administration of Off-the-Shelf, Expanded, Most Closely HLA Matched, Third Party Adenovirus Specific T Cells for Therapy of Adenovirus Related Disease in Immunocompromised Patients","Inclusion Criteria:\n\n* Immunocompromised patients.\n* English and non-English speaking patients.\n* Written informed consent and\u002For signed assent from patient, parent or guardian.\n* Negative pregnancy test in female patients of childbearing potential, defined as not post-menopausal for 12 months or no previous surgical sterilization. Women of child bearing potential must be willing to use an effective contraceptive measure while on study.\n* Patients age 1 year or older with asymptomatic adenovirus viremia defined as no symptoms of adenovirus disease and EITHER two positive and quantifiable qPCR tests taken one week apart or one single measurement with \\>\u002F= 1000 copies.\n* Patients age 1 year or older with criteria of probable or definitive adenoviral diseases as defined in Appendix A.\n* Willingness to comply with the study protocol requirements.\n\nExclusion Criteria:\n\n* Patients receiving prednisone \\> 0.1 mg\u002Fkg\u002Fday or equivalent at time of enrollment, or who have received anti-thymocyte globulin (ATG) within 14 days or have received donor lymphocyte infusion (DLI) or Campath within 28 days of enrollment.\n* Patients with other uncontrolled infections: For bacterial infections, patients must be receiving therapy and have no signs of progressing infection for 72 hours prior to enrollment. For fungal infections patients must be receiving anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollment. Progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.\n* Active acute graft versus host disease (GVHD) grade \\>= 2.",{"count":86,"type":19},16,[88],"PHASE1","This phase I trial studies the side effects of allogeneic adenovirus-specific cytotoxic T lymphocytes (donor T cell therapy) and to see how well they work in treating patients with a weakened immune system (immunocompromised) and adenovirus-related disease. Allogeneic adenovirus-specific cytotoxic T lymphocytes are made from donated blood cells grown in the laboratory and are designed to kill viruses that can cause infections in immunocompromised patients with adenovirus-related disease.",[91,27],"Hematopoietic and Lymphoid Cell Neoplasm","2026-02-17",{"date":94,"type":40},"2026-02-19",{"date":96,"type":40},"2018-03-15",{"date":98,"type":19},"2027-01-01",{"name":100,"class":101},"M.D. Anderson Cancer Center","OTHER",1,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":4},"100623008","integrating-vaccination-into-hospital-care-pathways-for-vulnerable-patients-100623008","NCT07391046","Integrating Vaccination Into Hospital Care Pathways for Vulnerable Patients","Integrating Vaccination Into Hospital Care Pathways for Vulnerable Patients: A Scalable and Sustainable Model","AMBU-VAX","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Presence of at least one chronic or immunocompromising condition eligible for vaccination according to national guidelines\n* Written informed consent provided\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Conditions not included among the predefined eligibility criteria",{"count":112,"type":19},1500,"OBSERVATIONAL","AMBU-VAX is a prospective, single-center observational study designed to develop and implement an organizational model for delivering recommended vaccinations within a hospital setting.\n\nThe study targets adult and elderly patients with chronic diseases or immunocompromising conditions who are eligible for vaccination according to national immunization guidelines. Vaccination is actively proposed during outpatient visits, hospital admissions, or at discharge and, when accepted, administered within the hospital or coordinated with local public health vaccination services.\n\nThe study aims to evaluate the feasibility, uptake, and completion of hospital-based vaccination pathways and to support integration between hospital and territorial prevention services for vulnerable populations.",[116,27,117,118,119,120,121,122,123,124,125],"Chronic Disease","HIV Infection","Chronic Kidney Disease","Solid Organ Transplantation","Hematopoietic Stem Cell Transplantation","Cancer","Autoimmune Diseases","Inflammatory Bowel Disease","Asplenia","Frailty","NOT_YET_RECRUITING","2026-01-29",{"date":129,"type":40},"2026-02-05",{"date":131,"type":19},"2026-02",{"date":133,"type":19},"2027-02",{"name":135,"class":101},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":142,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":102},"100602204","clinical-study-on-immunogenicity-and-safety-of-lyophilized-vero-cell-derived-human-rabies-vaccine-in-special-populations-100602204","NCT07120464","Clinical Study on Immunogenicity and Safety of Lyophilized Vero Cell-Derived Human Rabies Vaccine in Special Populations","Inclusion Criteria:\n\n* Subjects with WHO category II or III rabies exposure presenting at the study site for post-exposure prophylaxis and vaccination.\n* Subjects planned to be included in the control group, aged 18 to less than 60 years old, healthy as confirmed by medical history, physical examination, and clinical judgment before vaccination.\n* Subjects planned to be included in the study group who meet any of the following conditions:\n\n  1. Long-term immunocompromised status due to conditions including, but not limited to: clinically confirmed primary immunodeficiency diseases; hematologic or solid organ malignancies; aplastic anemia; clinically confirmed autoimmune diseases with immunosuppressive therapy lasting 4 weeks or longer within the past 12 months prior to enrollment; history of splenectomy or other major immunologic organ removal; hematopoietic stem cell or solid organ transplantation within 2 years prior to enrollment.\n  2. Clinically confirmed diabetes mellitus, chronic hepatitis, liver cirrhosis, chronic glomerulonephritis, nephrotic syndrome, or chronic renal insufficiency.\n  3. Age 60 years or older.\n* Subjects or their legally authorized representatives are able to understand the study requirements and procedures, voluntarily agree to participate, and sign the informed consent form.\n* Subjects are able to comply with all planned follow-up visits and provide valid identification documents of themselves and\u002For their legally authorized representatives.\n\nExclusion Criteria:\n\n* History of previous rabies vaccination.\n* History of human immunodeficiency virus (HIV) infection.\n* Other conditions deemed unsuitable for participation in the clinical study by the investigator.",true,{"count":144,"type":19},180,"This study adopts a parallel-controlled design and includes a study group and a control group. The study group will enroll 150 special population participants (including non-HIV-related immunocompromised individuals, patients with chronic diseases, and elderly individuals) who receive their first post-exposure treatment following WHO category II or III rabies exposure. The control group will include 30 healthy adults with similar exposure.\n\nBlood samples will be collected at Day 14 and Day 90 after completion of the full vaccination schedule to assess rabies virus neutralizing antibody seroconversion rates and titers. Immunogenicity and antibody persistence will be compared between the two groups. Additionally, all adverse events occurring within 30 minutes and within 7 days after each dose will be recorded to evaluate safety.",[147,27,116],"Rabies Exposure",[149,150,151,152,153],"Immunocompromised Patients","Chronic Diseases","Elderly Population","Rabies Vaccine","Vaccine Immunogenicity","2025-08-06",{"date":156,"type":40},"2025-08-13",{"date":158,"type":19},"2025-08-15",{"date":160,"type":19},"2026-12-31",{"name":162,"class":47},"Liaoning Chengda Biotechnology CO., LTD",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":167,"acronym":33,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":20,"phases":171,"briefSummary":172,"conditions":173,"keywords":174,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":182,"locationsCount":102},"100563013","extended-remdesivir-infusion-combined-with-nirmatrelvirritonavir-for-persistent-sars-cov-2-infection-in-immunocompromised-patients-100563013","NCT06610643","Extended Remdesivir Infusion Combined With Nirmatrelvir\u002FRitonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Receive B-cell depletion therapy or bendamustine within 6months\n* Laboratory confirmed SARS-CoV-2 infection\n* Symptoms onset within 72 hours\n* NIAID ordinal score 0-5 upon enrollment\n\nExclusion Criteria:\n\n* Prior use of any anti-SARS-CoV-2 agents within 2 weeks. Remdesivir or NMV\u002Fr initiated within 24 hours is acceptable\n* Life expectancy \\< 1 month\n* Previous adverse effect related to remdesivir or NMV\u002Fr\n* Concurrent use medicine with drug-drug interaction with NMV\u002Fr\n* Patients receiving intubation and mechanical ventilation\n* eGFR \\< 30\n* Child pugh score Class C\n* Any other condition that in the opinion of the investigator would jeopardize the safety or rights of a subject participating in the trial or would render the subject unable to comply with the protocol.",{"count":170,"type":19},40,[60],"To evaluate the safety and efficacy of extended remdesivir infusion, targeting on immunocompromised individuals who had positive SARS-CoV-2 PCR despite an oral antiviral agent prescription.",[28,33,27],[175],"Extended RDV infusion combination therapy for SARS-CoV-2 infection in immunocompromised patients","2024-09-24",{"date":178,"type":40},"2024-09-25",{"date":180,"type":19},"2024-09-21",{"date":160,"type":19},{"name":183,"class":101},"National Taiwan University Hospital"]